Lancet On Covaxin
- All
- News
- Videos
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covaxin Safe, Phase 3 Results Needed To Assess Effectiveness, Says Lancet
Covaxin, the homegrown coronavirus vaccine that was authorized for use in January before full clinical trial data, has been declared "safe, immunogenic with no serious side effects" by Lancet that has published its phase 2 results.
-
Covaxin Phase 1 Trial Clears Lancet Review, Phase 3 Trial Ongoing
Covaxin, India's first indigenous vaccine against COVID-19, showed enhanced immune response without any serious side effects in the Phase 1 trials, according to the results published in well-respected Lancet Infectious Disease journal on Friday.
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covaxin Safe, Phase 3 Results Needed To Assess Effectiveness, Says Lancet
Covaxin, the homegrown coronavirus vaccine that was authorized for use in January before full clinical trial data, has been declared "safe, immunogenic with no serious side effects" by Lancet that has published its phase 2 results.
-
Covaxin Phase 1 Trial Clears Lancet Review, Phase 3 Trial Ongoing
Covaxin, India's first indigenous vaccine against COVID-19, showed enhanced immune response without any serious side effects in the Phase 1 trials, according to the results published in well-respected Lancet Infectious Disease journal on Friday.
